keyword
MENU ▼
Read by QxMD icon Read
search

Adalimumab

keyword
https://www.readbyqxmd.com/read/28812127/-uveitis-in-juvenile-idiopathic-arthritis
#1
I Foeldvari, K Walscheid, A Heiligenhaus
BACKGROUND: Uveitis is the most common extra-articular manifestation of juvenile idiopathic arthritis (JIA). It occurs, according to German registry data, in around 12% of JIA patients and can lead to a loss of vision, especially in cases of delayed diagnosis and/or inadequate therapy. OBJECTIVE: A review of current aspects of diagnosis and therapy was carried out. MATERIAL AND METHODS: This is a review article of the current literature. RESULTS: The risk of uveitis is significantly elevated in patients with an oligoarticular course of JIA, ANA positivity and young age at onset of JIA...
August 15, 2017: Zeitschrift Für Rheumatologie
https://www.readbyqxmd.com/read/28809993/adalimumab-in-chronic-plaque-psoriasis-a-clinical-guide
#2
Jashin J Wu, W C Valdecantos
<p>Psoriasis is a common, inflammatory disease that manifests itself as lesions on the skin, which greatly impacts the physical and psychological wellbeing of those affected. The current goal of treatment in psoriasis is to improve the signs and symptoms of disease, whilst minimizing the burden of disease on patient health-related quality of life. Psoriasis can also be associated with other comorbidities such as joint disease, cardiovascular disease, and depression, which can add to the complexity of treatment...
August 1, 2017: Journal of Drugs in Dermatology: JDD
https://www.readbyqxmd.com/read/28804988/patterns-of-systemic-treatment-for-psoriatic-arthritis-in-the-united-states-2004-2015
#3
Moa P Lee, Joyce Lii, Yinzhu Jin, Rishi J Desai, Daniel H Solomon, Joseph F Merola, Seoyoung C Kim
OBJECTIVE: To examine trends in use of systemic disease-modifying antirheumatic drugs (DMARD) among patients with psoriatic arthritis (PsA) in the U.S. METHODS: Using claims data (2004-2015) from a large U.S. commercial healthplan, we identified patients with PsA who initiated DMARDs. We examined baseline patient characteristics and initial treatment patterns. We then assessed changes in the DMARD regimen over the 12-month period after the 1(st) DMARD initiation date...
August 13, 2017: Arthritis Care & Research
https://www.readbyqxmd.com/read/28798049/patient-reported-outcomes-from-a-phase-3-study-of-baricitinib-versus-placebo-or-adalimumab-in-rheumatoid-arthritis-secondary-analyses-from-the-ra-beam-study
#4
Edward C Keystone, Peter C Taylor, Yoshiya Tanaka, Carol Gaich, Amy M DeLozier, Anna Dudek, Jorge Velasco Zamora, Jose Arturo Covarrubias Cobos, Terence Rooney, Stephanie de Bono, Vipin Arora, Bruno Linetzky, Michael E Weinblatt
BACKGROUND: To assess the effect of baricitinib on patient-reported outcomes (PROs) in patients with active rheumatoid arthritis and an inadequate response to methotrexate (MTX). METHODS: In this double-blind phase 3 study, patients were randomised 3:3:2 to placebo (n=488), baricitinib 4 mg once daily (n=487), or adalimumab 40 mg biweekly (n=330) with background MTX. PROs included the SF-36, EuroQol 5-D (EQ-5D) index scores and visual analogue scale, Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F), Health Assessment Questionnaire-Disability Index (HAQ-DI), Patient's Global Assessment of Disease Activity (PtGA), patient's assessment of pain and Work Productivity and Activity Impairment Questionnaire-Rheumatoid Arthritis (WPAI-RA), and measures collected in electronic patient daily diaries: duration and severity of morning joint stiffness (MJS), Worst Ttiredness and Worst Joint Pain...
August 10, 2017: Annals of the Rheumatic Diseases
https://www.readbyqxmd.com/read/28797990/marked-improvement-in-gastric-involvement-in-beh%C3%A3-et-s-disease-with-adalimumab-treatment
#5
Akira Sonoda, Ryo Ogawa, Kazuhiro Mizukami, Kensuke Fukuda, Mitsutaka Shuto, Kazuhisa Okamoto, Osamu Matsunari, Tadayoshi Okimoto, Kazunari Murakami
Gastric involvement is the least frequent manifestation of Behçet's disease, and effective treatment for it unknown. Here the case of a patient with gastric involvement in Behçet's disease that was markedly improved with adalimumab therapy is presented. A 68-year-old man developed an oral ulcer, erythema, folliculitis, and arthralgia. Behçet's disease was suspected; then, prednisolone and colchicine were administered. Esophagogastroduodenoscopy showed a punched-out ulcer in the posterior wall of the gastric antrum...
August 9, 2017: Turkish Journal of Gastroenterology: the Official Journal of Turkish Society of Gastroenterology
https://www.readbyqxmd.com/read/28796080/prospective-comparison-of-preference-and-efficacy-of-adalimumab-and-infliximab-for-treating-ulcerative-colitis-naive-to-antitumor-necrosis-factor-therapy
#6
Tsutomu Mizoshita, Takahito Katano, Satoshi Tanida, Atsuyuki Hirano, Tomokatsu Miyaki, Keiji Ozeki, Yuka Suzuki, Naomi Sugimura, Hiromi Kataoka, Takashi Joh
There have been few reports on 2 tumor necrosis factor alpha inhibitors, infliximab and adalimumab, with respect to patient preference and efficacy in ulcerative colitis (UC).We used questionnaires to evaluate the preference and reasons for drug choice between infliximab and adalimumab in UC patients naive to antitumor necrosis factor alpha therapy. We also analyzed the efficacy of infliximab and adalimumab prospectively and endoscopically before treatment and at 14 and 54 weeks.Of the 25 UC patients, infliximab and adalimumab were chosen by 10 (40%) and 15 (60%), respectively...
August 2017: Medicine (Baltimore)
https://www.readbyqxmd.com/read/28791873/comparing-biologic-persistence-and-healthcare-costs-in-rheumatoid-arthritis-patients-initiating-subcutaneous-biologics
#7
Anagha Nadkarni, Donna McMorrow, Robert Fowler, David Smith
AIM: Comparing biologic persistence and healthcare costs between rheumatoid arthritis (RA) patients initiating first- or second-line subcutaneous abatacept, adalimumab, or etanercept. MATERIALS & METHODS: Retrospective, observational cohort study, which included adults with RA who initiated either of the three treatments between 29 July 2011 and 1 July 2015. Total healthcare costs were measured during baseline and follow-up. Biologic persistence was compared using multivariable Cox proportional hazards regression...
August 9, 2017: Journal of Comparative Effectiveness Research
https://www.readbyqxmd.com/read/28791718/dried-blood-spots-from-finger-prick-facilitate-therapeutic-drug-monitoring-of-adalimumab-and-anti-adalimumab-in-patients-with-inflammatory-diseases
#8
E L Kneepkens, M F Pouw, G J Wolbink, T Schaap, M T Nurmohamed, A de Vries, T Rispens, K Bloem
BACKGROUND: Development of a self-sampling method for therapeutic drug monitoring (TDM) of biologicals will enhance TDM implementation in routine care and pharmacokinetic knowledge. AIM: To compare adalimumab and anti-adalimumab antibody (ADA) concentration measurements in dried blood spots (DBS) obtained from finger prick with measurements in serum obtained via venepuncture, from patients with rheumatic inflammatory diseases. METHODS: In this cross-sectional study, 161 consecutive patients were included...
August 9, 2017: British Journal of Clinical Pharmacology
https://www.readbyqxmd.com/read/28789636/drug-persistence-and-need-for-dose-intensification-to-adalimumab-therapy-the-importance-of-therapeutic-drug-monitoring-in-inflammatory-bowel-diseases
#9
Lorant Gonczi, Zsuzsanna Kurti, Mariann Rutka, Zsuzsanna Vegh, Klaudia Farkas, Barbara D Lovasz, Petra A Golovics, Krisztina B Gecse, Balazs Szalay, Tamas Molnar, Peter L Lakatos
BACKGROUND: Therapeutic drug monitoring (TDM) aid therapeutic decision making in patients with inflammatory bowel disease (IBD) who lose response to anti-TNF therapy. Our aim was to evaluate the frequency and predictive factors of loss of response (LOR) to adalimumab using TDM in IBD patients. METHODS: One hundred twelve IBD patients (with 214 TDM measurements, CD/UC 84/28, male/female 50/62, mean age CD/UC: 36/35 years) were enrolled in this consecutive cohort from two referral centres in Hungary...
August 8, 2017: BMC Gastroenterology
https://www.readbyqxmd.com/read/28777015/is-weekly-dose-of-adalimumab-a-simple-approach-for-resistant-psoriasis
#10
Sara Mazzilli, Arianna Zangrilli, Mauro Bavetta, Luca Bianchi
Backgroud: In real life, dose escalation can be a good approach for increasing efficacy in a subgroup of patients with an insufficient response to biologic therapy, reducing the signs and symptoms of psoriasis and improving the quality of life (QOL). OBJECTIVE: To determine the effectiveness of escalating adalimumab dosage from 40 mg eow to 40 mg weekly in a patient affected by psoriasis (PsO) and psoriatic arthritis (PsA) with < PASI 50 response following 364 weeks treatment...
August 4, 2017: Journal of Dermatological Treatment
https://www.readbyqxmd.com/read/28762213/comparative-effectiveness-of-adalimumab-versus-secukinumab-for-the-treatment-of-psoriatic-arthritis-a-matching-adjusted-indirect-comparison
#11
Vibeke Strand, Keith A Betts, Manish Mittal, Jinlin Song, Martha Skup, Avani Joshi
INTRODUCTION: The Phase III FUTURE I and II trials demonstrated the clinical efficacy of secukinumab in active psoriatic arthritis (PsA). In the absence of head-to-head trials, this study compared the clinical efficacy and cost effectiveness of adalimumab 40 mg versus secukinumab 150 and 300 mg for the treatment of active PsA. METHODS: A matching-adjusted indirect comparison was conducted using individual patient data from the ADEPT trial of adalimumab and published data from FUTURE I and II...
July 31, 2017: Rheumatology and Therapy
https://www.readbyqxmd.com/read/28756234/anti-tumor-necrosis-factor-with-a-glyco-engineered-fc-region-has-increased-efficacy-in-mice-with-colitis
#12
Felicia M Bloemendaal, Alon D Levin, Manon E Wildenberg, Pim J Koelink, Bradford L McRae, Jochen Salfeld, Jenifer Lum, Marijn van der Neut Kolfschoten, Jill W Claassens, Remco Visser, Arthur Bentlage, Geert R A M D'Haens, J Sjef Verbeek, Gestur Vidarsson, Gijs R van den Brink
BACKGROUND & AIMS: Although tumor necrosis factor (TNF) antagonists reduce many clinical features of inflammatory bowel disease (IBD), complete mucosal healing occurs in less than 50% of patients. The Fc region of monoclonal antibodies against TNF has immunosuppressive properties via effects on macrophage polarization. We examined the interaction between the anti-TNF Fc region and Fcγ receptors (FcγR), and whether the absence of the Fc core fucose (which increases binding to FcγRIIIa) increases the efficacy of anti-TNF in mice with colitis...
July 26, 2017: Gastroenterology
https://www.readbyqxmd.com/read/28755394/clinical-similarity-of-the-biosimilar-abp%C3%A2-501-compared-with-adalimumab-after-single-transition-long-term-results-from-a-randomised-double-blind-52-week-phase-3-study-in-moderate-to-severe-plaque-psoriasis-patients
#13
K Papp, H Bachelez, A Costanzo, P Foley, M Gooderham, P Kaur, S Philipp, L Spelman, N Zhang, B Strober
BACKGROUND: ABP 501, an FDA- and EMA-approved biosimilar, is highly similar to adalimumab in structure, function, and pharmacokinetics. OBJECTIVE: Demonstrate similarity in efficacy, safety, and immunogenicity of ABP 501 versus adalimumab for moderate-to-severe plaque psoriasis. METHODS: Patients were randomised (1:1) to receive ABP 501 or adalimumab 40 mg every 2 weeks for 16 weeks. At Week 16, patients with ≥50% improvement from baseline in psoriasis area-and-severity index score (PASI) were eligible to continue to Week 52...
July 28, 2017: British Journal of Dermatology
https://www.readbyqxmd.com/read/28753181/real-life-anti-tumour-necrosis-factor-experience-in-500-paediatric-united-kingdom-inflammatory-bowel-disease-patients
#14
Victoria M Merrick, Kajal Mortier, Linda J Williams, Rafeeq Muhammed, Marcus Kh Auth, Mamoun Elawad, John Me Fell, R Mark Beattie, Sabarinathan Loganathan, Franco Torrente, Mary-Anne Morris, Charles Charlton, Nick M Croft, Astor Rodrigues, Mark Furman, Babu Vadamalayan, Huw Jenkins, Veena Zamvar, Sally G Mitton, Sonny Chong, Mike Cosgrove, Anthony Akobeng, David C Wilson, Richard K Russell
OBJECTIVES: To measure the effectiveness, safety and use of anti-Tumour necrosis Factor (TNF) therapy in paediatric inflammatory bowel disease (PIBD) in the United Kingdom (UK). METHODS: Prospective UK audit of patients newly starting anti-TNF therapy. Disease severity was assessed using Physician Global Assessment (PGA) +/or the Paediatric Crohn's Disease Activity Index (PCDAI). RESULTS: 37 centres participated (23 of 25 specialist PIBD sites)...
July 27, 2017: Journal of Pediatric Gastroenterology and Nutrition
https://www.readbyqxmd.com/read/28752637/anti-tnf-treatment-in-crohn-s-disease-and-risk-of-bowel-resection-a-population-based-cohort-study
#15
M Eberhardson, J K Söderling, M Neovius, T Cars, P Myrelid, J F Ludvigsson, J Askling, A Ekbom, O Olén
BACKGROUND: TNF inhibitors (TNFi) have been shown to reduce the need for surgery in Crohn's disease, but few studies have examined their effect beyond the first year of treatment. AIM: To conduct a register-based observational cohort study in Sweden 2006-2014 to investigate the risk of bowel resection in bowel surgery naïve TNFi-treated Crohn's disease patients and whether patients on TNFi ≥12 months are less likely to undergo bowel resection than patients discontinuing treatment before 12 months...
July 28, 2017: Alimentary Pharmacology & Therapeutics
https://www.readbyqxmd.com/read/28752504/die-oralen-auswirkungen-von-morbus-crohn-beschreibung-von-neun-f%C3%A3-llen
#16
Tuncay Sahin, Alexandre Brygo, Emmanuel Delaporte, Joël Ferri
Crohn’s disease (CD) is a chronic inflammatory bowel disease whose oral features remain underrated at clinical examination. The aim of the study was to report forerunner orofacial presentations leading to diagnosis of CD among nine patients of mean age 23 between 2008 and 2015. Linear ulcerative buccal lesions, cobblestoning, mucosal tags and perioral erythema are highly evocative and might precede intestinal signs for several years. Oral biopsies revealed highly suggestive lesions of CD for 45% of patients before any intestinal symptom or digestive investigation...
2017: Swiss Dental Journal
https://www.readbyqxmd.com/read/28752126/adalimumab-associated-bullous-pemphigoid-in-a-patient-with-ulcerative-colitis
#17
Laurel L Wessman, Elizabeth K Blixt, David A Wetter, Rachel Y Miest
No abstract text is available yet for this article.
July 2017: JAAD Case Reports
https://www.readbyqxmd.com/read/28747060/treatment-persistence-during-therapeutic-sequences-with-adalimumab-and-infliximab-in-the-treatment-of-crohn-s-disease
#18
Carlos Taxonera, Pilar Robledo, Antonio Rodriguez
BACKGROUND AND AIM: Tumor necrosis factor (TNF) inhibitors have demonstrated efficacy and safety in the treatment Crohn's disease (CD). However, the loss of response over time means that they are usually used sequentially. The aim of this study was to compare treatment persistence with different sequences of TNF inhibitors in patients with active luminal CD. METHODS: A Markov model (3-month cycles) was developed to simulate the therapeutic sequences of beginning biological treatment with infliximab or adalimumab, with a time horizon of three years...
July 27, 2017: Revista Española de Enfermedades Digestivas
https://www.readbyqxmd.com/read/28747057/prevalence-risk-factors-and-response-to-treatment-of-extra-intestinal-manifestations-in-patients-with-inflammatory-bowel-disease
#19
María Hernández-Tejero, Alicia Granja Navacerrada, Pilar Bernal Checa, Rubén Piqué Becerra, Alicia Algaba García, Iván Guerra Marina, Francisco Javier García-Alonso, Mariano Syed, Fernando Bermejo
INTRODUCTION: Patients with inflammatory bowel disease can experience extra-intestinal manifestations that may cause significant morbidity. AIMS: To describe the prevalence, characteristics, treatment and evolution of extra-intestinal manifestations in inflammatory bowel disease patients treated in our hospital and to identify associated risk factors. METHODS: This was a retrospective, observational, case-control study. All inflammatory bowel disease patients with extra-intestinal manifestations were considered as cases and inflammatory bowel disease patients without extra-intestinal manifestations were considered as controls...
July 27, 2017: Revista Española de Enfermedades Digestivas
https://www.readbyqxmd.com/read/28745108/comparison-of-drug-survival-and-clinical-outcome-in-patients-with-ankylosing-spondylitis-treated-with-etanercept-or-adalimumab
#20
J Ruwaard, M J l'Ami, A F Marsman, E L Kneepkens, J C van Denderen, I E van der Horst-Bruinsma, M T Nurmohamed, G Wolbink
OBJECTIVE: To compare rates of drug survival and clinical response during 2 years of follow-up in ankylosing spondylitis (AS) patients treated with etanercept or adalimumab in routine care. METHOD: Biological-naïve consecutive AS patients treated with etanercept (n = 163) or adalimumab (n = 82) were followed. Treatment discontinuation was due to inefficacy, adverse events, loss to follow-up, planning a pregnancy, or uveitis. Disease activity was assessed by the Ankylosing Spondylitis Disease Activity Score using C-reactive protein (ASDAS-CRP)...
July 26, 2017: Scandinavian Journal of Rheumatology
keyword
keyword
1884
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"